Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

Схожие документы

• Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
  по: Su, Po-Lan, et al.
  Опубликовано: (2018)
• Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan
  по: Chun-Hui Lee, et al.
  Опубликовано: (2022-05-01)
• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  по: Xu, Jianlin, et al.
  Опубликовано: (2016)
• Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
  по: Chang, Yi-Sheng, et al.
  Опубликовано: (2018)
• Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
  по: Arrieta, Oscar, et al.
  Опубликовано: (2020)